Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04037865 · ClinicalTrials.gov registry record · Phase 1
A Renal Impairment Study for PF-06651600
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT04037865 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 8 participants.
The verdict
NCT04037865, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a Phase 1 non-randomized, open-label, parallel cohort study of PF-06651600 in subjects with severe renal impairment and subjects without renal impairment (Part 1) and in subjects with mild and moderate renal impairment (Part 2).
Interventions
- DRUG PF-06651600
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2019-08-19 |
| Est. Completion | 2020-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04037865
The ClinicalTrials.gov registry entry for NCT04037865 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-06651600 is the first listed.
NCT04037865 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04037865 about?
NCT04037865 is a clinical study titled "A Renal Impairment Study for PF-06651600". This is a Phase 1 non-randomized, open-label, parallel cohort study of PF-06651600 in subjects with severe renal impairment and subjects without renal impairment (Part 1) and in subjects with mild and moderate renal impairment (Part 2).
What is the current status of trial NCT04037865?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2019-08-19. Estimated completion is 2020-03-31.
What interventions are being tested in trial NCT04037865?
The interventions under investigation include: PF-06651600 (DRUG).
Who is sponsoring clinical trial NCT04037865?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.